GRAIL is trading at $150.24, up 10.01%, as gains extend after an FDA advisory panel voted in favor of Galleri, its multi-cancer detection test. - On September 23, panelists voted 7-2 that Galleri’s benefits outweighed its risks. - The FDA makes the final decision, and its ruling is pending; a September 30 report cited the panel decision as the reason for the ongoing rise.